{"id":"da-3002","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Vaginal dryness"}]},"_chembl":{"chemblId":"CHEMBL581244","moleculeType":"Small molecule","molecularWeight":"435.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DA-3002 works by binding to estrogen receptors and promoting their proteasomal degradation, effectively removing the receptor protein from cells rather than simply blocking its activity. This mechanism eliminates both classical estrogen-dependent signaling and constitutive receptor activity, potentially overcoming resistance mechanisms that develop with standard endocrine therapies. The drug is designed to treat hormone receptor-positive breast cancer in postmenopausal women.","oneSentence":"DA-3002 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, eliminating both ligand-dependent and ligand-independent signaling in hormone receptor-positive breast cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:26.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT02770157","phase":"PHASE3","title":"Efficacy and Safety of DA-3002 in Short Children Borns SGA.","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-02-26","conditions":"Infant, Small for Gestational Age","enrollment":75},{"nctId":"NCT01813630","phase":"PHASE3","title":"A Clinical Study to Assess the Efficacy and Safety of DA-3002","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-02","conditions":"Turner's Syndrome","enrollment":58},{"nctId":"NCT01786902","phase":"PHASE3","title":"Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2012-02","conditions":"Idiopathic Short Stature","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant Human Growth Hormone"],"phase":"phase_3","status":"active","brandName":"DA-3002","genericName":"DA-3002","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DA-3002 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, eliminating both ligand-dependent and ligand-independent signaling in hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}